N-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)喹唑啉-2-胺 | 913067-91-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: N-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)喹唑啉-2-胺
• 中文别名: 2-甲基氨基喹唑啉-6-硼酸频哪醇酯；N-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-2-氨基喹唑啉
• 英文名称: N-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinazolin-2-amine
• CAS: 913067-91-1
• 化学式: C₁₅H₂₀BN₃O₂
• 分子量: 285.154
• InChiKey: DIHAVMAMDKOAGT-UHFFFAOYSA-N

物化性质

• 沸点：
  450.1±37.0 °C(Predicted)
• 密度：
  1.14

计算性质

• 辛醇/水分配系数(LogP)：
  1.97
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  56.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  N-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)喹唑啉-2-胺 在 四(三苯基膦)钯 、 caesium carbonate 、 N,N-二异丙基乙胺 、 三氟乙酸 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 11.0h， 生成 1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-4-(2-(methylamino)quinazolin-6-yl)-1H-pyrazole-3-carboxamide
  参考文献：
  名称：

  [EN] ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS
  [FR] COMPOSÉS ARYLE, HÉTÉROARYLE, ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES MÉDICAUX

  摘要：

  公开号：

  WO2017035353A8
• 作为产物：
  描述：

  5-溴-2-氟苯甲醛 在 tris(dibenzylideneacetone)dipalladium (0) 、 potassium acetate 、 对甲苯磺酸 、 N,N-二异丙基乙胺 、 2-(二环己基膦基)联苯 作用下， 以 1,4-二氧六环 、 N-甲基吡咯烷酮 为溶剂， 80.0~160.0 ℃ 、5.65 MPa 条件下， 反应 24.0h， 生成 N-甲基-6-(4,4,5,5-四甲基-1,3,2-二氧硼戊环-2-基)喹唑啉-2-胺
  参考文献：
  名称：

  Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck:  Synthesis, SAR, and in Vivo Anti-Inflammatory Activity

  摘要：

  The lymphocyte-specific kinase (Lck) is a cytoplasmic tyrosine kinase of the Src family expressed in T cells and natural killer (NK) cells. Genetic evidence in both mice and humans demonstrates that Lck kinase activity is critical for signaling mediated by the T cell receptor (TCR), which leads to normal T cell development and activation. Selective inhibition of Lck is expected to offer a new therapy for the treatment of T-cell-mediated autoimmune and inflammatory disease. Screening of our kinase-preferred collection identified aminoquinazoline 1 as a potent, nonselective inhibitor of Lck and T cell proliferation. In this report, we describe the synthesis and structure-activity relationships of a series of novel aminoquinazolines possessing in vitro mechanism-based potency. Optimized, orally bioavailable compounds 32 and 47 exhibit anti-inflammatory activity (ED50 of 22 and 11 mg/kg, respectively) in the anti-CD3-induced production of interleukin-2 (IL-2) in mice.

  DOI：

  10.1021/jm0605482

文献信息

• Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline
  作者：Adrian L. Smith、Frenel F. DeMorin、Nick A. Paras、Qi Huang、Jeffrey K. Petkus、Elizabeth M. Doherty、Thomas Nixey、Joseph L. Kim、Douglas A. Whittington、Linda F. Epstein、Matthew R. Lee、Mark J. Rose、Carol Babij、Manory Fernando、Kristen Hess、Quynh Le、Pedro Beltran、Josette Carnahan

  DOI：10.1021/jm901081g

  日期：2009.10.22

  The discovery and optimization of a novel series of aminoisoquinolines as potent, selective, and efficacious inhibitors of the mutant B-Raf pathway is presented. The N-linked pyridylpyrimidine benzamide 2 was identified as a potent, modestly selective inhibitor of the B-Raf enzyme. Replacement of the benzamide with an aminoisoquinoline core significantly improved kinase selectivity and imparted favorable

  提出并优化了一系列新颖的氨基异喹啉类作为突变B-Raf途径的有效，选择性和有效抑制剂。N-连接的吡啶基嘧啶苯甲酰胺2被确定为B-Raf酶的有效，适度选择性抑制剂。用氨基异喹啉核心取代苯甲酰胺可显着改善激酶选择性，并赋予良好的药代动力学特性，从而在异种移植模型中鉴定出1为有效的抗肿瘤药。
• Nitrogen-containing bicyclic heteroaryl compounds and methods of use
  申请人：De Morin F. Frenel

  公开号：US20070185324A1

  公开（公告）日：2007-08-09

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R 1 is and A 1 , A 2 , A 3 , A 4 , X, Z, Z′, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新的化合物类别，能够调节Raf激酶，因此有助于治疗由Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症相关的疾病。该化合物具有通用的I式，其中R1为，A1、A2、A3、A4、X、Z、Z'、R2、R3、R4、R5和R6在此被定义。本发明还包括制备本发明化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。
• Aryl nitrogen-containing bicyclic compounds and methods of use
  申请人：Patel F. Vinod

  公开号：US20070054916A1

  公开（公告）日：2007-03-08

  The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation, cancer and related conditions. The compounds have a general Formula I wherein A 1 , A 2 , A 3 , B, R 1 , R 2 , R 3 and R 4 are defined herein. Accordingly, the invention also comprises pharmaceutical compositions comprising the compounds of the invention, methods for the prophylaxis and treatment of kinase mediated diseases using the compounds and compositions of the invention, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一种新的化合物类别，对蛋白激酶介导的疾病，包括炎症、癌症和相关疾病的预防和治疗有用。该化合物具有一般的式子I，其中A1、A2、A3、B、R1、R2、R3和R4在此定义。因此，本发明还涉及包含本发明化合物的制药组合物，使用本发明化合物和组合物预防和治疗激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。
• PYRAZINOPYRAZINES AND DERIVATIVES AS KINASE INHIBITORS
  申请人：Huang Wei-Sheng

  公开号：US20110288078A1

  公开（公告）日：2011-11-24

  This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

  本发明涉及以下通式的化合物：其中变量基团如本文所定义，以及它们的制备和使用。
• Substituted quinazolinamine compounds for the treatment of cancer
  申请人：Amgen Inc.

  公开号：US07989461B2

  公开（公告）日：2011-08-02

  The present invention comprises a new class of compounds capable of modulating Raf kinase and, accordingly, useful for treatment of Raf kinase mediated diseases, including melanomas, tumors and other cancer-related conditions. The compounds have a general Formula I wherein R1 is and A1, A2, A3, A4, X, Z, Z′, R1, R2, R3, R4, R5 and R6 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of Raf kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新型化合物，能够调节Raf激酶，因此适用于治疗Raf激酶介导的疾病，包括黑色素瘤、肿瘤和其他与癌症有关的疾病。这些化合物具有一般式I，其中R1为，A1、A2、A3、A4、X、Z、Z'、R1、R2、R3、R4、R5和R6在此定义。本发明还涉及制备本发明化合物的中间体和方法，以及用于治疗Raf激酶介导的疾病的制药组合物。